Would you like to take part in an Asthma Research study?

Kia ora Island Bay School,

My name is Claire Houghton, I am a doctor and researcher at the Medical Research Institute of New Zealand (MRINZ) based in Wellington Hospital.


The MRINZ is currently running a study for children with asthma, and the team wondered if we might be able to share a community notice about it with parents by placing it in the next school Newsletter and/or on a school notice board, if you felt this was appropriate.

Please find attached a study poster. We can adapt a graphic to be simpler and smaller to fit the newsletter better if you don’t have space for it in this format.

It would also be useful to include contact details for the study in the newsletter. We can be contacted for more information using any of the following methods:

More information: https://trials.mrinz.ac.nz/surveys/?s=XFL7DL98HD

Our study website: https://www.mrinz.ac.nz/currently-recruiting/care-study

Email: care@mrinz.ac.nz

Telephone: +64 4 805 0250 / +64 4 805 0201

We have had great uptake in the Greater Wellington area and are keen to make sure that as many whānau as possible have the opportunity to take part.

I look forward to hearing from you.

Ngā mihi nui,

Claire


More info


Children’s Anti-inflammatory REliever (CARE) study


Rationale

One in seven children in NZ have asthma. This is one of the highest rates in the world. The impact on

children is significant, with asthma accounting for 4.4 days off school, up to 10% of all NZ general practice

(GP) consultations for children, and more than 3000 hospital admissions, every year.

Many children only use a short-acting reliever (“blue”) inhaler (“puffer”), such as Ventolin or Respigen, which

provides fast symptom relief, but does not treat swelling in the lungs that is often present; this can increase

the risk of asthma attacks.

Two recent studies in adults found that Symbicort (an inhaler that combines a long-acting reliever and a

weak steroid) taken only when needed was more effective than short-acting relievers at controlling asthma.

In particular, Symbicort reduced asthma attacks by more than half. The 2020 NZ adolescent and adult

asthma guidelines were changed in response to these findings, recommending that Symbicort be used

instead of short-acting relievers.

There have been no similar studies in children; if comparable efficacy of this regimen is shown in childhood

asthma, then its implementation would transform international guideline recommendations and has the

potential to markedly reduce asthma morbidity globally.


Study design

The CARE study has been designed by a team of international asthma experts and paediatricians. The aim

of the study is to find out if there is a difference in the number of asthma attacks between the two treatments.

To do this, we plan to enrol 380 children across New Zealand. All children who take part will be randomly

assigned to use Ventolin (a short-acting reliever) or Symbicort Rapihaler (a long-acting reliever with a weak

steroid) for 1 year.

During the study, participants will attend five visits, at 13-weekly intervals. Three visits will be conducted in

person at the Medical Research Institute of New Zealand (MRINZ) in Wellington Hospital or at the Lower

Hutt After Hours Medical Centre (participant choice) and two via telephone. Visit procedures include

completing asthma questionnaires and performing basic breathing tests.

The CARE study is sponsored by the MRINZ, and funded by the Health Research Council of New Zealand

(20/389) and Cure Kids. It is approved by the Northern B Health and Disability Ethics Committee

(20/NTB/200) and the Standing Committee on Therapeutic Trials (20/SCOTT/98).


Benefits to participants

 Participants will receive regular asthma education, training, and contact from an experienced team of

asthma researchers.

 Study inhalers are provided free of charge throughout the study.

 Participants enrolled into research studies tend to have better outcomes.

 Parent(s)/guardian(s) of participants will receive $50 per in-person visit attended to cover the cost of

transport.


Benefits to Schools

 You will be assisting with world-leading research that could help to reduce the:

o Asthma burden in children, including reducing time missed from school due to asthma.

o Asthma burden on school staff, due to time spent managing poorly controlled asthma.

Recent Posts

See All

Kids Art with Dan at the Southern Cross

Kids creativity opportunity at the Southern Cross next Tues 5th & Fri 8th 1-3pm. Chill out & enjoy a coffee or brunch whilst your children spend an afternoon with artist Dan Wilkinson as he guides the